Larvol Delta - CNS-Pharmaceuticals-Continues-to-Execute-on-Corporate-Clinical-and-Regulatory-Strategies-to-Drive-Berubicin-Towards-Commercialization-for-the-Treatment-of-GBM

berubicin (RTA 744) - CNS Pharma, WPD Pharma

https://www.prnewswire.com/news-releases/cns-pharmaceuticals-continues-to-execute-on-corporate-clinical-and-regulatory-strategies-to-drive-berubicin-towards-commercialization-for-the-treatment-of-gbm-301324229.html

Jul 1, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next